Who Paid My Doc
Ori Ben-Yehuda
Cardiovascular Disease San Diego, CA Medical Doctor
NPI 1508912387 CMS profile 1061046
4168 Front St, Mail Code - 8411, San Diego, CA 92103
General payments
$23,504
Research payments
$0
Ownership & investment interest
$299,580
Research they led as principal investigator
$341,160
Through program year 2025, Ori Ben-Yehuda of San Diego, CA is reported in the CMS Open Payments database as having received $23,504 across 33 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $341,160 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $299,580 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $137 | 2 | |
| 2024 | General | $22,414 | 20 | |
| 2023 | General | $122 | 1 | |
| 2022 | General | $573 | 4 | |
| 2021 | General | $203 | 3 | |
| 2020 | General | $17 | 1 | |
| 2019 | General | $39 | 2 | |
| 2025 | Ownership | $149,999 | 1 | |
| 2024 | Ownership | $149,582 | 1 |
Beside peers
- Ori Ben-Yehuda
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Ori Ben-Yehuda were reported at $137. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Ori Ben-Yehuda | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $39 | $450 | $127–$1,392 | $163 |
| 2020 | $17 | $242 | $77–$751 | $114 |
| 2021 | $203 | $335 | $101–$1,037 | $132 |
| 2022 | $573 | $395 | $121–$1,211 | $149 |
| 2023 | $122 | $443 | $136–$1,283 | $160 |
| 2024 | $22,414 | $450 | $136–$1,323 | $164 |
| 2025 | $137 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 32 drugsPart D claims
1,551
Drug cost
$346,380
Branded share of claims
22.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 101 | $125,922 | |
| Entresto Sacubitril/Valsartan | Brand | 88 | $83,591 | |
| Jardiance Empagliflozin | Brand | 50 | $60,012 | |
| Farxiga Dapagliflozin Propanediol | Brand | 22 | $27,650 | |
| Xarelto Rivaroxaban | Brand | 21 | $13,211 | |
| Corlanor Ivabradine Hcl | Brand | 11 | $9,798 | |
| Ezetimibe | Generic | 189 | $8,881 | |
| Metoprolol Succinate | Generic | 122 | $1,709 | |
| Verapamil Sr Verapamil Hcl | Brand | 14 | $1,590 | |
| Rosuvastatin Calcium | Generic | 63 | $1,542 |
The 10 drugs with the highest cost, of 32 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 22 billing codesPaid by Medicare
$51,249
Medicare patients
226
Services billed
709
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 69% | |
| Heart failure | 57% | |
| Arthritis | 53% | |
| Atrial fibrillation | 51% | |
| Chronic kidney disease | 47% | |
| Diabetes | 41% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
33 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in California
Ted Love
Cardiovascular Disease · Hillsborough, CA
Paul Kurth
Cardiovascular Disease · Santa Barbara, CA
Jason Rogers
Cardiovascular Disease · Sacramento, CA
Matthew Budoff
Cardiovascular Disease · Torrance, CA
Eric Topol
Cardiovascular Disease · La Jolla, CA
Cathleen Bairey-Merz
Cardiovascular Disease · Los Angeles, CA
Related records
Cardiovascular Disease in California
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.